gimli
MANKIND stock analysis context
MANKIND PHARMA Stock Context for AI Screening
MANKIND PHARMA LIMITED is a large-cap stock in Healthcare. This page summarizes key screening signals for MANKIND PHARMA, including recent returns, momentum indicators, valuation ratios, liquidity, and growth metrics. Gimli uses this context to help users ask natural-language stock screening questions across Indian equities.
Ask Gimli about MANKINDPrice
₹2,479.40
1M return
+10.94%
3M return
+22.48%
Market cap
₹102,356.65 cr
PE
62.11
ROE
+13.65%
RSI
62.34
Turnover
₹168.69 cr
Why it can matter in screens
- Momentum: MANKIND is above 50DMA, above 200DMA; RSI is 62.34.
- Returns: 1M +10.94%, 3M +22.48%, 6M +10.58%.
- Liquidity: latest turnover is ₹168.69 cr.
- Valuation: PE 62.11, PB n/a, ROE +13.65%, ROCE +16.86%.
- Growth: 3Y sales CAGR +16.19%, 3Y profit CAGR +11.57%.
Try these prompts
- Analyze MANKIND PHARMA with valuation, momentum and industry peers
- Compare MANKIND with other Healthcare stocks
- Show large-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View large-cap stocks
- Find stocks above 50DMA
- Compare MANKIND with other Healthcare stocks
Data snapshot: 2026-05-22. Not investment advice.